Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570411 | 1.00 | MEN1 (0.40) | MEN1KMT2ASLC6A3KEAP1NFE2L2 | |
| SCHEMBL5689417 | 0.80 | SLC6A3 (0.42) | MEN1KMT2ASLC6A3KEAP1NFE2L2 | |
| SCHEMBL5686699 | 0.74 | SLC6A3 (0.45) | MEN1KMT2ASLC6A3KEAP1NFE2L2 | |
| SCHEMBL11387493 | 0.73 | MEN1 (0.46) | MEN1KMT2ASLC6A3KEAP1NFE2L2 | |
| SCHEMBL2729130 | 0.73 | CES1 (0.46) | KMT2ACHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL8197545 | 0.73 | SLC6A3 (0.37) | MEN1KMT2ASLC6A3KEAP1NFE2L2 | |
| SCHEMBL8374252 | 0.73 | MEN1 (0.40) | MEN1KMT2ASLC6A3 | |
| SCHEMBL29005522 | 0.73 | MEN1 (0.40) | MEN1KMT2ASLC6A3 | |
| SCHEMBL8633571 | 0.72 | MEN1 (0.41) | MEN1KMT2ASLC6A3MGLLALDH1A1 | |
| SCHEMBL9315916 | 0.72 | SLC6A3 (0.39) | SLC6A3MGLLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7261836-B2 | Chiral dopant with phenylethanediol functionality | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2007-08-28 | — | — | US | disclosed |
| US-20060022167-A1 | Chiral dopant with phenylethanediol functionality | KONINKLIJKE PHILIPS ELECTRONICS N.V. | 2006-02-02 | — | — | US | disclosed |
| EP-1519910-A1 | CHIRAL DOPANT WITH PHENYLETHANEDIOL FUNCTIONALITY | Koninklijke Philips Electronics N.V. (NL) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004002935-A1 | CHIRAL DOPANT WITH PHENYLETHANEDIOL FUNCTIONALITY | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060022167-A1 | Chiral dopant with phenylethanediol functionality | CRY2, CRY1, DDT | MEN1 1406/4885KMT2A 1814/4885SLC6A3 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.